Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Jerald Sadoff, Glenda Gray, An Vandebosch, +27

New England Journal of Medicine

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Jorma Paavonen, Paulo Naud, Jorge Salmerón, +24

The Lancet

As04-adjuvanted VaccineGynecologyOncogenic Hpv TypesCancer-associated VirusCervical Cancer Prevention +14

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Cosette M. Wheeler, Xavier Castellsagué, Suzanne M. Garland, +24

The Lancet Oncology

VaccinationVaccine SafetyCervical Cancer ScreeningPreventive MedicineCervical Cancer +12

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

Jerald Sadoff, Glenda Gray, An Vandebosch, +26

New England Journal of Medicine

Immunization of Early Adolescent Females with Human Papillomavirus Type 16 and 18 L1 Virus-Like Particle Vaccine Containing AS04 Adjuvant

Court Pedersen, Tiina Petäjä, Gitte Strauss, +8

Journal of Adolescent Health

VaccinationEarly Adolescent FemalesVaccine DevelopmentHuman Papillomavirus VaccinesImmunology +4

Evaluation of Safety, Immunogenicity and Efficacy of an Attenuated Rotavirus Vaccine, RIX4414

Beatriz Salinas, Irene Pérez Schael, Alexandre C. Linhares, +8

The Pediatric Infectious Disease Journal

One virus, one lesion—individual components of CIN lesions contain a specific HPV type

Wim Quint, David Jenkins, Anco Molijn, +8

The Journal of Pathology

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials

Dominique Descamps, Karin Hardt, Bart Spiessens, +4

Human Vaccines

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

Cosette M. Wheeler, S. Rachel Skinner, Maria Rowena Del Rosario‐Raymundo, +33

The Lancet Infectious Diseases

VaccinationVaccine SafetyVaccinologyViviane StudyPrecancerous Lesions +10

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

S. Rachel Skinner, Anne Szarewski, Barbara Romanowski, +25

The Lancet

VaccinationVaccine SafetyVaccinologyViviane StudyPrecancerous Lesions +11